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Abstract
Cell‐based therapeutics, such as in vitro manufactured red blood cells (mRBCs), are
different to traditional biopharmaceutical products (the final product being the cells
themselves as opposed to biological molecules such as proteins) and that presents a
challenge of developing new robust and economically feasible manufacturing pro-
cesses, especially for sample purification. Current purification technologies have
limited throughput, rely on expensive fluorescent or magnetic immunolabeling with
a significant (up to 70%) cell loss and quality impairment. To address this challenge,
previously characterized mechanical properties of umbilical cord blood CD34+ cells
undergoing in vitro erythropoiesis were used to develop an mRBC purification
strategy. The approach consists of two main stages: (a) a microfluidic separation
using inertial focusing for deformability‐based sorting of enucleated cells (mRBC)
from nuclei and nucleated cells resulting in 70% purity and (b) membrane filtration
to enhance the purity to 99%. Herein, we propose a new route for high‐throughput
(processing millions of cells/min and mls of medium/min) purification process for
mRBC, leading to high mRBC purity while maintaining cell integrity and no altera-
tions in their global gene expression profile. Further adaption of this separation
approach offers a potential route for processing of a wide range of cellular products.
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1 | INTRODUCTION
Stem cell‐derived red blood cells could constitute an attractive
pathogen‐free and sustainable alternative for donated blood for rare
blood groups and patients requiring regular transfusions (Zeuner
et al., 2012). In many cases, such as sickle cell anemia, myelodys-
plasias and leukemia, multiple blood transfusion is regarded as the
only available symptomatic treatment, and that can lead to im-
munization against the allogeneic red blood cells and transfusion
impasses (Douay & Andreu, 2007). The efficient production of man-
ufactured red blood cells (mRBCs) is consequently an ambitious goal
for blood services around the world; however, production of a single
therapeutic dose (~2 × 1012 cells) still remains a significant challenge
(Cabrita et al., 2003; Peyrard et al., 2011). Clinical application of
mRBC is currently hampered by a lack of technological solutions that
would allow production of mRBC at a satisfactory scale and purity in
compliance with good manufacture practice (GMP) regulations within
the realms of economic feasibility (Bayley et al., 2018; Li, Wu, Fu, &
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Han, 2013; Migliaccio, Whitsett, Papayannopoulou, & Sadelain, 2012;
Rousseau, Giarratana, & Douay, 2014; Shah, Huang, & Cheng, 2014).
To date, mRBC have been produced from several sources of
starting material: CD34+ hematopoietic stem cells from peripheral
blood (PB) (G. Migliaccio et al., 2002) and umbilical cord blood (CB)
(Baek et al., 2008; Fujimi et al., 2008; Neildez‐Nguyen et al., 2002),
peripheral blood mononuclear cells (Akker, Satchwell, Pellegrin, Daniels,
& Toye, 2010), embryonic (Lu et al., 2008; Ma et al., 2008) and induced
pluripotent stem cells (iPSCs; Lapillonne et al., 2010) and recently
immortalized adult human erythroid line (Bristol Erythroid Line Adult
BEL‐A; Trakarnsanga et al., 2017). In the last 15 years, considerable
progress has been achieved in terms of optimizing biological processes
underpinning erythroid cell expansion and maturation (Migliaccio,
Masselli, Varricchio, & Whitsett, 2012). The selection of starting cell
material such as iPSC and BEL‐A cell lines offers a potentially unlimited
source for in vitro erythroid differentiation while mitigating blood‐
compatibility issues. Moreover, all xenogeneic culture compounds, for
example, serum, transferrin, insulin, and growth factors, have been re-
placed, resolving the associated risks of virus, prions, and immunological
complications (Grillberger, Kreil, Nasr, & Reiter, 2009; Migliaccio
et al., 2010; Miharada, Hiroyama, Sudo, Nagasawa, & Nakamura, 2006;
Timmins, Athanasas, Gunther, Buntine, & Nielsen, 2011). A mini‐
transfusion (1011 cells) of autologous CB CD34+ derived mRBC (under
GMP conditions) was given to a patient in 2011, providing the proof of
principle of mRBC feasibility for clinical use (Giarratana et al., 2011;
http://www.clinicaltrials.gov; Emelyanenko, 2009).
Despite considerable progress in improving the expansion rate and
yield of mRBC, enucleation rates remain limited (Table S1). The end‐
product of existing differentiation protocols is consequently a hetero-
geneous mixture of enucleated mRBC, nucleated cells that remain at
earlier developmental stages and free‐floating nuclei expelled during
the enucleation process (Figure 1b). In 2008, Fujimi et al. (2008) re-
ported a differentiation strategy with CB CD34+ providing an almost
complete enucleation (99.4%) (Fujimi et al., 2008). However, this was
achieved by coculture with macrophages, making the protocol chal-
lenging to scale‐up (Goers, Freemont, & Polizzi, 2014). With lower
enucleation rates, the presence of residual nucleated cells and expelled
nuclei constitute a potential danger if intended for transfusion into
patients (Bouhassira, 2008; Guzniczak et al., 2017). Undifferentiated
nucleated cells can give rise to teratomas (benign tumors of differ-
entiating cells) and teratocarcinomas (malignant metastatic tumors
composed of highly proliferative cells; McGowan, Campbell, &
Mountford, 2018), thus they have to be removed from the sample and
require adequate purification approaches. In addition, presence of free‐
floating nuclei in large quantities may prove particularly problematic in
large‐scale culture systems by fouling surfaces and entangling the de-
sired cell product in DNA (Timmins & Nielsen, 2011)
Traditionally, cell purification is performed using fluorescent or
magnetic activated cell sorting (FACS or MACS) (Schriebl, Lim, Choo,
Tscheliessnig, & Jungbauer, 2010). FACS and MACS both generate
highly defined, purified (>95%) cell populations with a low number of
unwanted cells in the final product; however, the requirement for cell‐
specific ligands hinders adaptation of these methods to industrial‐scale
processing due to the high cost of antibodies. In addition, im-
munolabeling is a laborious multi‐step process consisting of numerous
centrifugation, washing, and incubation steps often resulting in a sig-
nificant (reported up to 70%) cell loss (Schriebl et al., 2010) and post‐
isolation cell quality impairment (Lee et al., 2018). Currently, only a
limited number of fluorophore‐conjugated antibody reagents are sui-
table for clinical processing (McIntyre, Flyg, & Fong, 2010) and the
adverse effects of introducing these probes into patients are unknown,
but it is generally recognized that they could potentially trigger im-
mune and toxic responses (Willoughby et al., 2016). Various alter-
natives to FACS and MACS for cellular therapies, such as mRBC
production, have been proposed and were recently reviewed (Masri,
Hoeve, Sousa, & Willoughby, 2017). Recent work on deterministic
lateral displacement (Campos‐Gonzalez et al., 2018) and inertial
(a) (b)
(c)
F IGURE 1 (a) Cord blood (CB) CD34+ cells undergo in vitro
differentiation into manufactured red blood cells (mRBCs) over the
course of 21 days. (b) As shown in the exemplary cytospin image, the
end‐product of the differentiation protocol is a heterogeneous
population containing enucleated mRBC, partially differentiated or
undifferentiated nucleated cells as well as free‐floating nuclei. The scale
bar corresponds to 20 µm. (c) The proposed label‐free sorting strategy
for the end‐product consists of two steps: first, the sample is processed
in a spiral microchannel with a rectangular cross‐section (170× 30 um2),
six loops, one inlet, and four outlets (A, B, C, and D). Inertial focusing
within spiral microchannels occurs due to balance of shear gradient lift
force (FL), wall‐induced lift force (FW) as well as Dean drag (FDD).
Particles of different sizes interact with a different section of the
characteristic cross‐sectional velocity profile (Dean vortices).
Deformable particles experience an additional deformability‐induced lift
force (FD). Cells align in the spiral channel at distinct lateral equilibrium
positions, that facilitates their capture in one of the four outlets. The
majority of the desired enucleated cells is captured in outlet A with some
contaminant nucleated cells, which are further removed by membrane
filtration [Color figure can be viewed at wileyonlinelibrary.com]
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vortexes (Pritchard et al., 2019) have demonstrated application to
CAR‐T cell processing and inertial focussing has been used to isolate,
enrich, and purify stem cells (Hur, Brinckerhoff, Walthers, Dunn, &
Di Carlo, 2012; Lee et al., 2018; Song et al., 2017), to obtain desired
subpopulation (Lee et al., 2011, 2014; Poon et al., 2015), to isolate
single cells from clusters (Nathamgari et al., 2015), for nonviable cell
removal (Kwon, Yao, Hamel, & Han, 2018) as well as microcarrier
scaffold removal (Moloudi et al., 2018).
To address the challenge of mRBC purification, we propose a label‐
free approach to separate cells at high throughput based on their
morphological (size) and mechanical (deformability) properties. As pre-
sented in Figure 1c, the process consists of two main steps: (a) a mi-
crofluidic separation using inertial focusing in spiral microchannel and
(b) membrane filtration. Due to its simplicity in operation, low manu-
facturing cost and proven scalability by parallelization (allowing pro-
cessing millions of cells per minute) inertial focusing in spiral channels
has been recognized as an attractive approach for high‐throughput cell
sorting (Gou, Jia, Wang, & Sun, 2018) for a wide range of applications
(for a comprehensive review, see Gou et al., 2018). Traditionally, spiral
microchannels have been used for sorting cells based on size differ-
ences. Cells traveling within the channel experience inertial lift force
(combination of shear gradient lift force [FL], wall‐induced lift force [FW],
and Dean drag [FDD]), and if cells travel a long enough distance, these
forces balance, focusing cells at distinct lateral equilibrium positions
(measured as a distance from the outer wall) depending on their size
(Bhagat, Kuntaegowdanahalli, & Papautsky, 2008; Gou et al., 2018). As
shown in Figure 1c, smaller nuclei are positioned closer to the inner wall
while larger cells are observed closer to the channel centreline. As we
previously reported (Guzniczak et al., 2020), there is a distinct hydro-
dynamic behavior of cells of the same size but different deformability at
sufficiently elevated flowrate. Stiff cells remain focused close to the
inner wall, while their softer counterparts experience additional drag (as
a consequence of the additional deformability‐induced lift force [FD];
Hur, Henderson‐MacLennan, McCabe, & Di Carlo, 2011) and they travel
across the channel to be equilibrated near the outer wall. Particles of
the same size but different deformability assemble at distinct equili-
brium positions within the channel cross‐section, hence cell deform-
ability can also be used as a sorting parameter.
In this study, the impact of deformability on the focusing me-
chanism has been translated into an effective label‐free purification
protocol for mRBC derived from cord blood CD34+ cells. This ap-
proach offers a viable alternative to FACS and MACS for sorting
mRBC at industrial scale in a label‐free manner at high purities and
without compromising cell quality, consequently creating a new route
to bring mRBC into clinical use.
2 | MATERIALS AND METHODS
2.1 | Differentiating CD34+ into red blood cells
The differentiation protocol was performed in accordance with
relevant guidelines and regulations and was approved by the
Heriot‐Watt Engineering and Physical Sciences Ethics Committee as
well as the Heriot‐Watt Engineering and Physical Sciences Biosafety
Review. Umbilical cord blood CD34+ cells were purchased from Stem
Cell Technologies and differentiated using a modified version of a
protocol described previously (Griffiths et al., 2012). Cells were
cultured for 21 days in basal growth medium: Iscove's basal medium
(cat. BCHRFG0465; VWR), 5% human AB+Serum (cat. H4522; Sigma‐
Aldrich), 3 U/ml heparin (cat. H5515; Sigma‐Aldrich), 10 µg/ml insulin
(cat. 19278; Sigma‐Aldrich), and 200 µg/ml human holotransferrin
(cat. 616397‐500; VWR) supplemented as outlined in Table 1. At
each passaging occasion (Days 8, 11, 14, and 18), cells were
harvested by centrifugation at 200g for 5 min and resuspended in
fresh medium supplemented with appropriate compounds. All cell
culture manipulations were carried under aseptic conditions in a
cabinet with laminar air flow.
2.2 | Cell characterization
2.2.1 | Flow cytometry
Each population is characterized by a combination of molecular
markers such as presence/absence of DNA (DNA+/DNA−) and ex-
pression/lack of expression of glycophorin A (CD235a+/CD235a−).
Enucleated cells are DNA− and CD235a+, nucleated cells are DNA+
and CD235a+, free‐floating nuclei are DNA+ and CD235a+, however,
they express lower levels of CD235a than nucleated cells. Each
100 µl aliquot of cells (~1 × 106 cell/ml) suspended in phosphate‐
buffered saline (PBS) without calcium and magnesium (PBS−/−;
Gibco) was supplemented with 0.5% bovine serum albumin (Sigma‐
Aldrich), 0.625 µl of fluorescein isothiocyanate‐conjugated Mouse
Anti‐Human CD235a (cat. 559943; BD) and 0.5 µl of 5mM DRAQ5™
Fluorescent Probe (cat. 564902; BD). Cells were incubated for
20min at room temperature in darkness and the excess fluorescent
stain was not removed to prevent cell damage. Cells were analyzed
TABLE 1 Changing cell culture medium composition for the 21
days CB CD34+ differentiation protocol
Day Medium composition
0–8 60 ng/ml recombinant human stem cell factor (SCF) (cat.
300‐07; PeproTech)
5 ng/ml recombinant human IL‐3 (cat. 200‐03; PeproTech)
3 U/ml erythropoietin (EPO) (clinical grade material;
Roche)
1 µM hydrocortisone (cat. H0888; Sigma‐Aldrich)
8–14 10 ng/ml SCF
3U/ml erythropoietin
1 µM hydrocortisone
300 µg/ml holotransferrin
14–21 3U/ml erythropoietin
300 µg/ml holotransferrin
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on a flow cytometer (BD LSR II; BD) and data processed using FlowJo
V10 CL and GraphPad Prism 6.
2.2.2 | Real‐time fluorescence and deformability
cytometry
Cells' morphological and mechanical properties were assessed
using real‐time fluorescence and deformability cytometry (RT‐FDC;
Rosendahl et al., 2018) (for detailed description of the technique,
see Supporting Information Material). Briefly, CB CD34+ cells were
harvested at the end of the differentiation protocol by cen-
trifugation at 200g for 5 min and resuspended in a 0.05% methyl-
cellulose solution (CellCarrier; Zellmechanik Dresden, Germany) to
reach a final concentration of 1–2 × 106 cells/ml. Due to their fra-
gile nature, cells were stained directly in CellCarrier by adding
5 mM DRAQ5™ Fluorescent Probe (BD) (to obtain a final con-
centration of 5 µM) per 100 µl buffer volume. Cells were incubated
for 2 min, in darkness at room temperature and analyzed im-
mediately after staining. CB CD34+ cells were injected in a
20 × 20 µm cross‐section channel at 0.12 µl/min for real time size
and deformability measurement. The gating strategy for enculated/
nucleated cells and nuclei is detailed in Figure 2 with data obtained
using the RT‐FDC software ShapeOut 0.8.4 (available at www.
zellmechanik.com).
2.3 | Cell morphology—cytospin
To visualize cells' morphology and structure, cells were transferred
onto microscope slides using a cytocentrifuge then fixed and stained
using Giemsa‐Wright staining (Rapid Romanowsky Stain Pack, cat.
SW167/500; TCS Bioscience). Cells were harvested by centrifugation
at 300g for 5min and resuspended at 2 × 106 cells/ml in PBS−/−
(Dulbecco's PBS buffer without calcium and magnesium; Gibco). One
hundred microliters of cell suspension was transferred into a cyto-
centrifuge cell funnel and centrifuged at 450 rpm for 4min in a cyto-
centrifuge (Cellspin I; Tharmac, Germany) to transfer the cells onto the
slide. Slides were then air‐dried for 15min, fixed, and stained ac-
cording to the manufacturer's instructions. After staining, slides were
air‐dried, then fixed with DePeX mounting medium (cat. 06522; Sigma‐
Aldrich). Slides were photographed for further image analysis using
either an EOS 60D Canon camera (Canon, UK) mounted on an AXIO
Scope.A1 Zeiss microscope (Zeiss, Germany) at ×100 magnification or
using a Canon 650d camera (Canon) mounted on a Motic AE31 mi-
croscope (Motic, UK) at ×40 magnification. Images were analyzed in
either Matlab R2016b using a custom‐made script or using bespoke
LabView software, which detected the outline of the cells and nuclei
by thresholding. The detected objects were classified into nucleated
cells, enucleated cells, and free‐floating nuclei, and the measurements
of the morphological features were extracted for further processing.
2.4 | Separation in spiral channels
2.4.1 | Microfluidic system
To sort mRBC from contaminant nucleated cells and free‐floating
nuclei a spiral channel with a rectangular cross‐section (30 µm deep
and 170 µm wide), six loops, one inlet, and four balanced outlets
(A, B, C, and D) were used (Figure 1 and Figure S10). Due to the
laminar flow regime, fluid flowing thought the channel is split into four
F IGURE 2 Gating strategy applied to characterize the end product of CB CD34+ in vitro erythropoiesis. The sample collected at the end of the
differentiation protocol was stained with a nuclear stain DRAQ5 to check for the presence of a nucleus. Each subpopulation can be characterized by a
combination of size and fluorescent signal. Enucleated cells are inherently negative for DNA (DRAQ5‐DNA−), nucleated cells are larger than the free‐
floating nuclei and both are DRAQ5‐DNA+. Events between 0 and 15µm2 were assumed to be cell debris and they were excluded from the analysis. (a)
Scatter plot of the area (µm2) versus deformability (−) for a control unstained sample for more than 20,000 acquired events. (b) Scatter plot of DRAQ5‐
DNA versus area (µm2) for the unstained sample. The gate splits the scatter plot into DNA‐negative region on the left hand side and DNA‐positive region
on the right hand side. (c) Scatter plot for the sample stained with DRAQ5 for the presence of DNA. Gates for each subpopulations are shown as color‐
coded rectangles: pink for enucleated cells, purple for nucleated cells and gray for nuclei [Color figure can be viewed at wileyonlinelibrary.com]
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equal portions, flowing with the same volumetric throughput into the
corresponding outlets. Microfluidic devices were fabricated by litho-
graphy in Poly(methyl methacrylate) (PMMA; Epigem, UK).
2.4.2 | Cell processing
The current differentiation protocol involves the use of human serum
as a supplement to cell culture media. It provides high concentrations
of growth factors, macromolecules, carrier proteins for lipids, trace
elements, attachment and spreading factors, nutrients, and hormones
(Heger et al., 2018). We however found, similarly to others
(Henderson et al., 2010), that microfluidic channels can clog with
serum (Henderson et al., 2010) and recommend using a serum‐free
buffer for processing. Moreover, the presence of phenol red (pH in-
dicator in basal medium) impairs reads from both flow cytometry and
automated cell count, thus cells processed in the basal medium could
not be directly sampled for the quality control tests. In this study, we
used PBS−/− supplemented with 0.1% biocompatible surfactant
Pluronic F‐68 (Guzniczak et al., 2018) (cat. 24040032; Thermo Fisher
Scientific) as a processing buffer. Pluronic F‐68 was added to sur-
rogate the serum protective mechanism from mechanical damages
(e.g. due to shear stress generated within the spiral microchannel)
(Heger et al., 2018; Tharmalingam, Ghebeh, Wuerz, & Butler, 2008;
Guzniczak et al., 2018).
Cells suspended in PBS−/− supplemented with 0.1% Pluronic F‐68
at circa 3–4× 106 cells/ml were injected in a spiral microfluidic channel
with a mid‐pressure syringe pump (neMESYS 1000N; Cetoni, Germany)
in 10‐ml batches trough 1/16” PTFE tubing of 0.5mm internal diameter
(Thames Restek, UK). Cell concentration is a critical factor influencing
focusing within the spiral microchannel. If the concentration is too high,
the steric crowding effect occurs, meaning that there is physically not
enough space for particles to focus in a tight single stream. To identify if
the crowding effect will occur, the parameter α (number of particle
diameters per channel length) can be calculated.
WHV
a
6
,F
2
α π=
(1)
where W (resp. H) the width (resp. height) of the channel cross
section, VF is the volume fraction of particles in the solution, a the
particle diameter. For α > 1, focusing to a single stream can be
challenged by steric interactions between particles (Di Carlo, 2009).
Assuming that all the particles in the input sample were of the size of
the largest nucleated cells (a~5 µm), at 3–4 × 106 cells/ml, α varies
between 0.153 and 0.255 giving an upperbound of α < 1.
As shown in Table 2, cells were examined at flow rates ranged from
200 to 1,000 µl/min (corresponding to channel Reynolds number [Re]
between 33 and 168, Dean number [De] ranging between 5 and 26).
The channel Re is a dimensionless parameter, which describes
the unperturbed channel flow.
Re
UDInertial forces
Viscous forces
,h
ρ
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where ρ is the medium density, Uis the medium velocity, μ is the
dynamic viscosity, and Dh is the hydraulic diameter, defined as
D
H W
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2
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where H is the channel height andW is the channel width.
De is used to quantify the secondary flow within spiral micro-
channel, and it is defined as
De Re
D
R
,h= (4)
where R is the radius of the curvature.
The focusing behavior of cells was assessed in terms of lateral
equilibrium position, measured as a distance from the cell center to
the outer wall of the spiral channel in region of interest as shown in
Figure S10B. Images of cells inside the spiral channel were recorded
at ×10 magnification with a 4.9 mm free working distance (421251‐
9911‐000 LD A‐Plan 10× Ph1; Zeiss) using high‐speed camera (CCD
ProgRes®; Jenoptik, Germany) mounted on a microscope (Zeiss Axio
Observer 3; Zeiss). Images were recorded at 130 frames per second
and analyzed using a bespoke MatLab script. To enhance the pur-
ification efficiency, cells collected in outlet A of the spiral channel
were passed through a 3 µm polycarbonate Isopore™ filter mem-
brane (Merc, UK). Cell suspension was loaded into a 5ml plastic
syringe and pumped through the filter membrane at 2ml/min using a
syringe pump (neMESYS; Cetoni). Cell suspensions were passed
through the filter membranes fitted onto syringe adapter and the
filtrate was collected in 10‐ml plastic tube. The sorting performance
was assessed using the following three parameters:
C
C
C
Separation efficiency
i
type outlet
type outlet
1
4
type outlet
i
i
i
[ ] = [ ]∑ [ ]=
(5)
of each cell type in each outlet, where Ctype[ ] is the concentration of
given cell type cells in a given outlet i (i =A, B, C, or D).
C
C
C
Purity 100%type outlet
type outlet
all outlet
i
i
i
[ ] = [ ][ ] ×
(6)
indicating a fraction of each subset in a sample collected after pro-
cessing, where Call[ ] is the concentration of all cell types found in the
sample and
TABLE 2 Table summarizing experimental conditions (applied flow
rates and corresponding velocities, Reynolds number [Re], and Dean
number [De])
Flow rate (ml/min) Velocity (m/s) Re (‐) De
0.2 0.65 33 5
0.4 1.3 66 10
0.6 1.9 97 15
0.8 2.6 132 21
1 3.3 168 26
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CC
Enrichment ratio .
type outlet
type inlet
i= [ ][ ]
(7)
Cell separation efficiency was quantified by flow cytometry (BD
LSR II; BD) to compare the fraction of each cell population (char-
acterized by unique fluorescent properties) in samples collected at
each outlet and after filtration. In addition, cell yield was assessed by
counting the number of cells at each outlet and after filtration using
MoxiZ automated cell counter (Orflo). Further data analysis was
performed using GraphPad Prism 6 and FlowJo V10 CL.
In terms of actual recovery, determined by total number of cells
collected versus total number of cells injected into the system, there
is a slight variation (~5%) since the sample is subjected to dilution
and sedimentation. Before the procedure, device is primed with
running buffer without cells, the dead volume was assessed as 1.5m,
which should be discarded, since it takes around 1min for the system
to stabilize, and we collect cell suspension after this time. Since the
processing time for one batch is 10min, the first portion of collected
suspension is slightly more concentrated than the very last one due
to sedimentation.
2.4.3 | Viability—trypan blue exclusion assay
Control cells were not passed through the device but they were
incubated on a bench outside of an incubator for the time of the
treated (spiral) sample processing in the spiral microchannels. Both
control and treated cells were recultured under normal conditions
for 1 hr, before the trypan blue viability assays: 100 µl of cell sus-
pension (control/treated cells) was mixed with an equal part of
0.4% trypan blue dye (Gibco, UK), incubated for less than 3min at
room temperature, loaded onto a glass haemocytometer and counted
using a light microscope (AXIO Scope.A1; Zeiss).
2.4.4 | Global gene expression
To assess whether cell processing within the spiral microchannel
results in global gene expression alterations, CB CD34+ cells un-
dergoing in vitro erythropoiesis collected at Day 14 of the differ-
entiation protocol were used. Both control (not passed through the
device but they were incubated on a bench outside of an incubator
for the time of the treated sample processing in the spiral micro-
channels) and treated cells after processing were recultured under
normal conditions for 24 hr and then harvested by centrifugation at
200g for 5min. The cell pellets were flash‐frozen by immersing in
liquid nitrogen batch and stored at −80°C until ready for RNA ex-
traction (performed using MagMAX™ mirVana™ Total RNA Isolation
Kit; Thermo Fisher Scientific, as indicated by the instruction manual).
The impact of filtration was not studied.
The global gene expression measurements by poly‐A selection
were performed by the Edinburgh Clinical Research Facility (https://
www.edinburghcrf.ed.ac.uk/Genetics) and run according to their in-
ternal standard operating procedures. The bioinformatic analysis
comprised of trimming N bases and the filtering of poor‐quality reads
(Phred‐score ≤ 30) with trim‐galore before aligning with HISAT2 to
the GRCh38 human genome (Ensembl version 94). Post alignment,
reads were sorted with SAMtools before quantifying explicit nor-
malized expression with the Cufflinks suite. Differential expression
analysis was performed using CuffDiff where significance was de-
termined at a false discovery rate ≤ 0.05 cut‐off.
3 | RESULTS
3.1 | Manufactured red blood cell purification
3.1.1 | Sample characterization
The first step to develop the label‐free strategy for purifying mRBC
from the contaminant nucleated cells and free‐floating nuclei was to
identify if there was a unique set of label‐free markers, such as cell
size and deformability that would allow characterization of each of
the subsets within the final product. These findings are detailed for
donor III in Guzniczak et al. (2017) and for donors I and II in Table S3
(for the convenience of the reader, also, data on donor III are in-
cluded in STable 3). The study was further conducted here for cells
from three different donors (see Figure 3 for exemplary data of one
replica from each donor).
As presented in Figure 3 and Table S3, the relative size measured
by flow cytometry as FSC‐A parameter shows that nucleated cells
always remain the largest in the samples (except for samples derived
from donor III, where they significantly overlap in size with enucleated
cells) and that was true across cells sourced from the three different
donors, nuclei always remain the smallest and the most rigid, while the
enucleated cells are the most deformable. Across the three researched
donors, there were discrepancies in the relative size of enucleated
cells and nuclei. Enucleated cells derived from donor I substantially
overlapped with sizes of nuclei (area under the curve [AUC] = 0.68,
Table S3) and the little shift was toward the larger side of the size
spectrum. For donor II, enucleated cells were the smallest within the
sample, while the subpopulation of enucleated cells derived from do-
nor III was larger than the subpopulation of the expelled nuclei
(AUC= 0.95) with a substantial overlap in terms of size with nucleated
cells (AUC= 0.56). For all the three donors, a separation based solely
on size would consequently lead to a relatively high likelihood of
contamination by nucleated cells or nuclei—the heterogeneity in cell
size from one donor to another could also be a challenge for channel
design and large scale processing. However, all the three donors lead
to mRBC (enucleated cells) that could be purified if sorting was based
on deformability. There were discrepancies between microscopy
measurements of size and those determined by FSC‐A, most probably
the consequence of the nature of sample preparation for each tech-
nique. In contrast to cytospin, flow cytometry allows size measure-
ment for live cells in suspension. FSC intensity produces a voltage
which is proportional to the cell diameter, however, cell size is not
reported in physical units. In the cytospin technique, deformable
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enucleated cells spread on the slide more than rigid nuclei, conse-
quently appearing larger than they really are. Thus, if the physical
value plays an important role (e.g., for fine‐tuning sorting device di-
mensions), a supplementary approach to flow cytometry is required.
3.1.2 | Process optimization
To identify optimal conditions to take advantage of deformability for
mRBC purification, the performance of a spiral microchannel with
170 × 30 µm2 cross‐section has been tested with FACS presorted
pure populations of enucleated and nucleated cells and nuclei from
donor III. As mentioned previously, nucleated and enucleated cells
sourced from this donor have a significant overlap in their size and
require a different strategy for sorting. Each subpopulation (en-
ucleated cells, nucleated cells and nuclei—sorted using FACS) was
run separately at gradually increasing flow rates (0.2, 0.4, 0.6, 0.8,
and 1ml/min; Figure 4a). The separation potential of enucleated cells
from nucleated and nuclei was estimated for each tested flow rate by
generating receiver operating curves curves and calculating the AUC
(Figure 4b). At lower flow rates (0.2, 0.4, and 0.6 ml/min), all three
subpopulations were pushed toward the inner wall. Enucleated and
nucleated cells occupy the same section of the channel (enucleated:
100 ± 24 µm, 123 ± 22 µm, and 131 ± 23 µm; nucleated: 110 ± 20 µm,
125 ± 15 µm, and 134 ± 11 µm [mean ± SD] at 0.2, 0.4, and 0.6 ml/min,
respectively) with a substantial overlap in the lateral equilibrium
position (AUC = 0.62, 0.51, and 0.52, for 0.2, 0.4, and 0.6 ml/min,
respectively) closer to the channel centreline. Increasing the flow
rate to 1ml/min triggered the characteristic shift, recently reported
and characterized in Guznizcak et al. (2020) of more deformable
enucleated cells toward the outer wall to the equilibrium lateral
position at 36 ± 21 µm, while less deformable nucleated cells re-
capitulated the unfocused transition pattern (103 ± 32 µm) observed
for enucleated cells at 0.8 ml/min (103 ± 33 µm). Except for the
lowest applied flow rate, nuclei always remained focused along the
inner wall in a tight stream (151 ± 23 µm at 0.4 ml/min, 156 ± 11 µm
at 0.6 ml/min, 158 ± 11 µm at 0.8ml/min, and 154 ± 18 µm at
1ml/min). In conclusion, theoretically, operating at 1ml/min flow rate
would allow separation of 96% of nucleated cells (AUC = 0.96) and
99% of nuclei (AUC = 0.99%) from the enucleated cells.
3.1.3 | Process performance
Differences in hydrodynamic behavior of enucleated and nucleated
cells, as well as nuclei observed at 1ml/min flow rate, were trans-
lated and incorporated into a label‐free purification process for
mRBC, derived from three donors (indicated as donor I, II, and III).
The heterogeneous end‐product after the differentiation protocol
was injected into the spiral microchannel at 1ml/min at a con-
centration of around 3 × 106 cells/ml. Figure 5a shows an averaged
fraction of each subset in the input sample derived from donors I, II,
and III. Enucleated cells constituted around 10–35% of the starting
sample. As predicted, due to their deformable nature, the majority of
enucleated cells were hydrodynamically directed to outlet A (closest
to the outer wall).
The high‐quality end‐product derived from donors I and III
constituted a good quality starting material for the label‐free pur-
ification resulting in highest separation efficiency (>90%) and purity
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F IGURE 3 The end product of CB CD34+ derived from donor I, II,
and III‐ in vitro differentiation into red blood cells. (a) Exemplary
image of the end product (input sample) for cells derived from donor
I. Scale bars correspond to 20 µm. (b) Size and deformability.
(c) Equal probability contour plots (the same number of cells fall
between each pair of contour lines) of deformation vs cell size
(expressed as projected cell area in µm2) for enucleated (pink) and
nucleated (purple) cells and nuclei (gray). (d) Histograms of FSC‐A
parameter reflecting relative sizes of enucleated and nucleated cells
as well as the free‐floating nuclei, measured by flow cytometry. The
number of events on each diagram is around 10,000—split
accordingly between each subpopulation [Color figure can be viewed
at wileyonlinelibrary.com]
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(>70%). In contrast, less abundant (Figure 3a), stiffer (Figure 3b), and
smaller (Figure 3c) enucleated cells derived from donor II were more
troublesome to purify. Their separation efficiency and purity in outlet
A were ~10% lower in comparison to donors I and III (Figure 5b).
Stiffer enucleated cells from donor II, probably, experience less of the
effect of FD, and they assemble the lateral equilibrium position closer
to the channel centreline resulting in their partial capture in outlet B
(separation efficiency: 12.3%, Figure 5b).
Transfusion of nucleated cells poses a leukemogenic risk (Zeuner
et al., 2012), thus this product should be further purified if intended
for clinical application, as a reasonable fraction of this cell type is
found in outlet A. This was achieved by adding a filtration step after
processing in the spiral channel (Figure 5c). Cells from donors I and II
collected at the outlets A were passed through 3 µm polycarbonate
Isopore™ filter membrane (see Supporting Information Mateiral;
SInfo – Filter membrane characterization for justification of the fil-
tration step) counted and assessed by flow cytometry. This enhanced
the purity of enucleated cells collected at outlet A to 99%. The high
purity, however, was a trade‐off for separation efficiency, since
during this process, 50–70% of enucleated cells were lost. It is im-
portant to note that current processing alternatives (such as FACS/
MACS) would lead to similar recoveries/purities while requiring ex-
pensive and potentially harmful immune‐labeling.
3.1.4 | Processing impact on cells
Inertial microfluidic techniques are considered as a gentle method for
biological samples processing, with significant literature evidence
supporting unaffected cell quality (e.g. viability, cell membrane in-
tegrity, proliferation, or altered gene expression) after processing
(Hur et al., 2011; L. M. Lee et al., 2018; W. C. Lee et al., 2011;
Nathamgari et al., 2015). However, elevated flow rates are required
to benefit from the deformability‐induced lift force. To investigate if
the hydrodynamically induced mechanical stress on the cells exerted
any adverse effect on the mRBC, phenotype cell integrity and global
gene expression profile were studied (Figure 6). The gene expression
study did not include any investigation of the impact of filtering.
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F IGURE 4 (a) The hydrodynamic behavior of presorted on
fluorescent activated cell sorting pure populations of enucleated
(pink) and nucleated (purple) cells and free‐floating nuclei (gray) as
well as 3, 5, 7, and 10 µm beads (shades of blue) was assessed in a
spiral microchannel with a 30 × 170 µm2 cross‐section at five
different flow rates: 0.2, 0.4, 0.6, 0.8, and 1ml/min. Lateral
equilibrium positions are measured as a distance from the outer wall
(µm) at the end of the spiral channel. Data reported as median
(represented as the longest vertical line) and the interquartile range
(indicated by the short vertical lines) on top of scatter plots, where
each dot represents one event. Around 200 events are shown for
each subpopulation. Vertical dotted lines indicate four sections of
the channel corresponding to four outlets of the channel (0–42.5 µm:
outlet A, etc.). (b) Receiver operating characteristic curves were
plotted for lateral equilibrium position for enucleated cells versus
nucleated cells and enucleated cells versus nuclei for each applied
flowrate. The true positive rate is defined as the number of
enucleated cells found at a given lateral position and divided by the
total number of enucleated cells. The false positive rate is the
corresponding number of nucleated cells (resp. nuclei) divided by the
total number of nucleated cells (resp. nuclei) for the same cut‐off. To
determine which of the applied flow rate ensures the best separation
efficiency the area under the curve was calculated [Color figure can
be viewed at wileyonlinelibrary.com]
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Populations of mRBC derived from donor I and II, at con-
centrations of ~3 × 106 cells/ml were processed in the spiral micro-
channel with 170 × 30 µm2 cross‐section at 1ml/min flow rate, and
eluents from all outlets were collected into one vial (labeled spiral)
and their quality was compared against unprocessed cells (control).
Cell integrity of the control and processed cells was investigated via
trypan blue exclusion assay. Live cells are impenetrable for trypan
blue, while damaged cells with impaired cell membrane integrity
uptake trypan blue and they appear blue. As shown in Figure 6a, the
high viability of >85% was comparable at the inlet (control) and after
processing (spiral).
Cells actively respond to mechanical perturbations through
the modification of gene expression (Miroshnikova, Nava, &
Wickstrom, 2017). To investigate if exposing undifferentiated nu-
cleated cells to mechanical stress engages oncogenes signaling
pathways, the global gene expression patterns were investigated
using poly‐A selection method. Control and processed (spiral) sam-
ples were collected earlier during the differentiation process
(Day 14) than samples for trypan blue assay, to ensure that nucleated
cells were still transcriptionally active.
After sequencing, a standard pipeline was run that seeks to de-
scribe the variance and correlative behavior across the data before
classifying those genes that are differentially expressed in each core
comparison. Sample by sample correlation analysis was performed to
attempt to ascertain how strongly or weakly each sample correlates
across the range of gene expression values (Spearman correlation
clustering, hierarchically clustered). A strong tendency for samples to
cluster by sample group (donors I and II), overriding the effects of
processing in the spiral microchannel (Figure 6b), was observed.
We then sought to describe the individual changes in gene expres-
sion using CuffDiff (Trapnell et al., 2013). Here, a small number of genes
changing significantly (p< .05) as a result of cell processing—40 and
42 changing genes in samples from donors I and II, respectively, was
observed. This was eclipsed by the scale of changes between sample
groups with over 2,400 changing (donor I vs donor II) at both the control
and treatment stages (Figure 6c).
Heatmaps of significantly differentially expressed genes
(Figure S9) show that although genes change in relatively robust
patterns, their expression changes are rarely recapitulated within
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F IGURE 5 The label‐free purification process of the end‐product
of CB CD34+ derived from donors I, II, and III‐ in vitro differentiation
into red blood cells, has been designed after (a) input sample
characterization in terms of purity. Exemplary image of the end
product (input sample) for cells derived from donor I. Scale bars
correspond to 20 µm. (d) Characterization of the label‐free
purification process for mRBC derived from three donors (indicated
as I, II, and III). The separation efficiency of enucleated cells from
contaminant nucleated cells and nuclei after processing in a spiral
channel with a 30 × 170 µm2 cross‐section and four outlets
(A ‐closest to the outer wall, B, C, and D) at 1 ml/min flow rate, and
enhanced by filtration. (e) The filtration step was performed only on
cells collected at the best performing outlet A. Both steps were
characterized by calculating purity and efficiency. The process
validation was performed with three replicas for donor I and II and
one, the bars representing the mean value and error bars the
standard error of the mean. Exemplary images for cells derived from
donor I, are shown for each step (input sample, postprocessing in
spiral microchannel and filtration). Scale bars correspond to 20 µm.
mRBC, manufactured red blood cell [Color figure can be viewed at
wileyonlinelibrary.com]
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treatment groups. In addition, as shown in the violin plots (Figure 6d),
for the two most upregulated and downregulated genes (selected by
the smallest p‐value), the level of changes are small when compared
to the spread in the expression levels between replicates.
In summary, it has been confirmed that mRBC, after processing
within the spiral microchannel at a sufficiently high flow rate to take
advantage of the effect of FD for cells focusing, retains a high degree
of viability and that there is no distinct or consistent gene expression
alteration.
4 | DISCUSSION
In this study, we successfully developed a passive, high‐throughput,
label‐free purification strategy for CB CD34+ derived red blood cells.
Using advances in the field of deformability cytometry, hetero-
geneous end‐products of CB CD34+ in vitro erythropoiesis were
characterized and label‐free markers were identified for the target
enucleated cells as well as contaminant nucleated cells and expelled
nuclei. These label‐free markers were used as a two‐step purification
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F IGURE 6 (a) Viability of mRBC derived from donor I and II, before (control) and after (spiral) processing in a spiral microchannel with
170 × 30 µm cross‐section at 1ml/min flow rate, measured by trypan blue exclusion assays. Bars represent mean fraction of live (plain green) or
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strategy: (a) using inertial focusing in a spiral microchannel where
most of the target enucleated cells are covered (>90%) at relatively
high purity (>70%), without compromising cell quality and (b) a
membrane filtration step resulting in the removal of ~99% of re-
maining impurities (mainly nucleated cells since >98% of nuclei were
removed by the spiral microchannel). The inertial focusing strategy is
based upon deformability sorting. Given the size of the overlap of the
enucleated and nucleated cells, the only explanation for the shift
toward the outer wall of the enucleated cells is the deformability
difference; this phenomena has been previously reported and char-
acterized, and although being a novel approach, further investigation
of the underlying theoretical physics, supported by experimental
data, is required (Guzniczak et al., 2020). The membrane filtration
step requires further optimization and development, since in this
study, dead‐end filtration, which is prone to membrane fouling, led to
the separation efficiency of 30–50% of enucleated cells. Shah et al.
(2016) reported a positive evaluation of CB CD34+ derived mRBC as
transfusion product (Shah et al., 2016), using their novel animal
model to assess the potential of mRBCs to deliver oxygen to muscle
tissues. To deplete undifferentiated nucleated cells before transfu-
sion, they used a nonwoven fabric filter (Tao, Xia, Cao, & Gao, 2011).
They carried out an extensive study on the impact of filtration on the
quality of mRBC and they found that cells, despite a significant cell
retention on the membrane (filtration removed ~75% of cells), mRBC
passed through the filter remained intact and there were no differ-
ence in levels of hemoglobin expression before and after filtration.
Gene expression changes were not studied by them, nor in our work.
In the demonstrated approach, >3 × 106 cells/min are processed
by a single device when operating at the optimal flow rate. The
downstream processing method proposed in this study has the ca-
pacity for further scale‐up by two means: increasing cell sample
concentration and system parallelization. However, the current cell
sample concentration seems reasonable for processing cells that are
routinely cultured within a similar concentration range in large vo-
lumes. At present, mRBC culture is routinely carried in static culture
conditions, facilitating maximal cell concentration at around 5 × 106
cells/ml (Rousseau et al., 2014). Volumetric throughput in the device
presented here is 1ml/min in a single layer system, which again is
compatible with the state‐of‐the art bioreactor sizes (Rousseau
et al., 2014), though larger volumes are likely to be required for
commercial production. Throughput could be improved by paralleli-
zation and/or stacking, for example, like recent work by Warkiani
that reached 240ml/min or 350 L/day, with the authors reporting
further parallelization was possible to triple the throughput
(Warkiani, Tay, Guan, & Han, 2015). Stacking microfluidic devices
(stack of 20 devices reported; Miller, Jimenez, & Bridle, 2016) is a
common practice resulting in a rapid and efficient throughput im-
provement. Further clarification is needed on exact requirements for
industrial‐scale production, though, given the lack of impact on the
cells of this approach, processing time is more likely to influence the
economics of the process rather than cell quality. Since the device
operates at elevated follow rate to reveal the differential equilibrium
position determined by deformability, one of the pragmatic
challenges would be to identify a suitable pumping system, with-
standing high pressures (up to 30 bars) and operating in a continuous
mode. Currently, cell suspensions are introduced into the device in
10ml batches using a mid‐pressure syringe pump.
Membrane filtration alone is less effective in processing the
mRBC than the combined process consisting of processing in spiral
microchannel followed by filtration. Particle separation by means of
filtration is a widely applied technique within field of bioprocessing
(Masri et al., 2017). Membrane filtration uses an average pore size
where particles larger than the pore size cannot pass through. Tra-
ditional membrane filtration suffers from several drawbacks, with the
main one being clogging. Clogged membrane filters degrade in per-
formance over time and the “filter cake” may pose contamination
hazards (Seo, Lean, & Kole, 2007). Membrane filtration is especially
problematic for mRBC purification due to presence of large quan-
tities of free‐floating nuclei. DNA is known for being “sticky” mole-
cule and causing fouling of surfaces (Timmins & Nielsen, 2011).
Inertial focusing in spiral microchannels has been proposed as
“membrane‐free” filtration, capable of continuous and high‐
throughput separation based on size and deformability (Bhagat
et al., 2008; Guzniczak et al., 2020). By processing the sample in
spiral microchannel, a majority (>98%) of the nuclei are depleted,
prolonging the life‐span of the filter membrane. The dead‐end
membrane filtration used in this study requires further optimization
and development to improve cell recovery.
All current protocols for the manufacture of RBC from stem cells
face the same technological challenge of low enucleation rate. The
most efficient solution is coculture with macrophages, which elim-
inate the expelled nuclei by the means of phagocytosis. This is an
organic solution but it comes with its own technological costs, such as
finding ways to retrieve the macrophages from the culture and the
complexity of a coculture system with feeder layer. In the most op-
timistic scenario, even if the enucleation rate is improved to reach
the desirable 100% and nucleated cells are not present in the end‐
product of the in vitro erythropoiesis, in the absence of macrophages,
the expelled nuclei will still remain within the sample. Having a ro-
bust label‐free procedure for mRBC purification at high‐throughput
with no impact on cell quality will consequently be of significant
importance for bringing mRBC a step closer to clinical use.
CB CD34+ cells are a limited and variable source of mRBC and as
verified in this study, starting cell material derived from different
donors give a final product characterized by different phenotypes
and mechanotypes, thus implementation of universal downstream
protocols is currently challenging. The field of stem cell‐derived
therapeutic products is maturing and with introduction of iPSC
(Lapillonne et al., 2010) and immortalized erythroid cell lines
(Trakarnsanga et al., 2017), it should be possible to produce large
quantities of standardized mRBC and integrate technology proposed
here into the formulation step of the cellular product derivation
process.
To conclude, this study presents a much‐needed label‐free high‐
throughput (millions of cells/min, ml of medium/min) scalable and
continuous cell sorting approach for novel stem‐cell‐derived
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therapeutic products. In addition, the capability to sort multiple cell
types simultaneously based on their size and deformability, at high‐
throughputs, within one system and without the compromising effect
of fluorescent labels could be highly relevant for isolation of various
cells of interest from heterogeneous samples.
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